Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celixir20
- Development stage
- Unknown
- Lead developer
- BOL Pharma
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Sublingual
01
Overview
**Celixir20** is a BOL Pharma cannabinoid-based sublingual medicated oil containing a high-cannabidiol, low-delta-9-tetrahydrocannabinol cannabis preparation. BOL Pharma describes Celixir20 as approved by the Israeli Ministry of Health for autism, while its medicated-drops portfolio identifies the formulation as approximately 20% cannabidiol and 1% delta-9-tetrahydrocannabinol. It has also been used in severe drug-resistant epilepsy, including pediatric patients, and has been listed for epilepsy in young adults and palliative care for hepatoma. The product is a chemically heterogeneous cannabis extract preparation rather than a single defined molecular entity. ([bolpharma.com](https://www.bolpharma.com/innovation/))
- Brand names
- Celixir20Celixir-20Celixir 20Noidecs T1:C20
02
Targets
GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR2 (Cannabinoid receptor type 2)
Beyond the preview
Go deeper on Celixir20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celixir20.